Recently, the Regulatory Authority Council issued a report that the Medical Device Single Audit Program (MDSAP) has been successful in its pilot, and will therefore continue. So what is the MDSAP and why is it important?
The medical device market has become increasingly more global, with the FDA estimating that imported medical devices made up 35% of the US market. Because of this, and regulators in other countries needing to conduct oversight of products originating in countries other than their own, a standardized global approach to auditing medical device manufacturers was needed.
Program goals included:
It goes without saying that for MDSAP to be successful multiple countries and their regulatory bodies would need to take part. Currently the five regulatory agencies taking part are Australia’s Therapeutic Goods Administration (TGA), Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), Health Canada, MHLW/PMDA (Japan), and the US Food and Drug Administration (FDA). Canada will also be transitioning from their Canadian Medical Devices Conformity Assessment System (CMDCAS) to the MDSAP system.
MDSAP allows for a recognized Auditing Organization (AO) to conduct a single, standardized regulatory audit on a medical device manufacturer. The five countries listed above will take part in MDSAP regulations. And while Europe does not take part in MDSAP, they may join in the future.
Participants in MDSAP are audited on a three-year cycle. The first, Initial Certification Audit is a complete audit of a medical device manufacturer’s quality management system. The remaining two Surveillance Audits are conducted once a year for the next two years. Once the initial three-year cycle ends, a new cycle begins with a Recertification Audit. It should be noted that other audits such as “for cause” inspections may still occur.
In the United States, the FDA will accept a MDSAP audit reports in place of most routine FDA inspections, except for “for cause” or compliance follow-up inspections. Another benefit MDSAP participants will receive are a lower risk profile under FDARA rules.
Additionally, by streamlining the regulatory process with the involvement of a singular regulatory body, medical device manufacturers should find a more uniform process, and less disruption in their business.
Criterion Edge is a regulatory writing company that provides outsourced writing services to the pharmaceutical and medical device industries. The company’s expertise in regulatory writing best practices, honed over decades, produces superior deliverables and provides budget, resource and timeline flexibility for regulatory managers. Criterion Edge empowers companies to deliver superior health care solutions. To learn more about how Criterion Edge can help you achieve your regulatory goals, click here to contact us, call us at 805-202-5520, or use the email: firstname.lastname@example.org.